Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease - Wikidata - awgldk - TriplyDB

Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease

Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease

http://www.wikidata.org/entity/Q35985806

about

Asymmetric dimethyarginine as marker and mediator in ischemic stroke Transsulfuration pathway thiols and methylated arginines: the Hunter Community Study The systemic nature of CKD.Dimethylarginines: endogenous inhibitors of nitric oxide synthesis in children with falciparum malaria.Estimated glomerular filtration rate is a poor predictor of the concentration of middle molecular weight uremic solutes in chronic kidney disease Circulating levels of dimethylarginines, chronic kidney disease and long-term clinical outcome in non-ST-elevation myocardial infarction.Symmetric dimethylarginine as predictor of graft loss and all-cause mortality in renal transplant recipients An update on uremic toxins.Transcriptome analysis in patients with chronic kidney disease on hemodialysis disclosing a key role for CD16+CX3CR1+ monocytes.Uraemic toxins and new methods to control their accumulation: game changers for the concept of dialysis adequacy Subtle renal dysfunction and bleeding risk in atrial fibrillation: symmetric dimethylarginine predicts HAS-BLED score Asymmetric and Symmetric Dimethylarginine as Risk Markers for Total Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Studies Symmetric Dimethylarginine Is Not Associated with Cumulative Inflammatory Load or Classical Cardiovascular Risk Factors in Rheumatoid Arthritis: A 6-Year Follow-Up Study.Association of dimethylarginines and mediators of inflammation after acute ischemic stroke Ageing/Menopausal Status in Healthy Women and Ageing in Healthy Men Differently Affect Cardiometabolic Parameters Challenges and opportunities for stem cell therapy in patients with chronic kidney disease Regular cigarette smoking influences the transsulfuration pathway, endothelial function, and inflammation biomarkers in a sex-gender specific manner in healthy young humans.Assessment of endothelial dysfunction: the role of symmetrical dimethylarginine and proinflammatory markers in chronic kidney disease and renal transplant recipients Asymmetric and symmetric dimethylarginine in adolescents with hyperuricemia.A zebrafish model for uremic toxicity: role of the complement pathway.Changes in biomarkers associated with living kidney donation.Protein-bound uremic toxins stimulate crosstalk between leukocytes and vessel wall.Toxic Dimethylarginines: Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA).Asymmetric dimethylarginine, endothelial dysfunction and renal disease The physical basis of renal fibrosis: effects of altered hydrodynamic forces on kidney homeostasis.Heart failure and kidney dysfunction: epidemiology, mechanisms and management.Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease.Effects of chronic SDMA infusion on glomerular filtration rate, blood pressure, myocardial function and renal histology in C57BL6/J mice.Kt/Vurea and Nonurea Small Solute Levels in the Hemodialysis Study.Serum amine-based metabolites and their association with outcomes in primary prevention implantable cardioverter-defibrillator patients.Determination of Asymmetric and Symmetric Dimethylarginine in Serum from Patients with Chronic Kidney Disease: UPLC-MS/MS versus ELISA.Symmetric Dimethylarginine Assay Validation, Stability, and Evaluation as a Marker for the Early Detection of Chronic Kidney Disease in Dogs."Uremic Toxin" Section in the Journal Toxins: A Powerful Tool to Bundle and Advance Knowledge on Uremia an Obituary for GFR as the main marker for kidney function?Symmetric Dimethylarginine in Cats with Hypertrophic Cardiomyopathy and Diabetes Mellitus.Effects of asymmetric dimethylarginine on inflammatory cytokines (TNF-α, IL-6 and IL-10) in rats.Platelet hyperaggregability in patients with atrial fibrillation. Evidence of a background proinflammatory milieu.Dimethylarginines in patients with intracerebral hemorrhage: association with outcome, hematoma enlargement, and edema.Is symmetric dimethylarginine a sensitive biomarker of subclinical kidney injury in children born with low birth weight?Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update.

P2860

Q26864318-35430F17-F42D-4133-AC17-970622A55F96 Q28485286-0DA56F8C-A060-4881-A572-0EAD761AEC3F Q30234695-5E35386E-33D1-4B08-862D-ECF57AC58AB4 Q34315639-B3F4C5E8-EE88-4ACA-A524-BC0A565C61DE Q34406428-E317A0AB-6731-4AF5-AA76-C97F68818D11 Q34489684-535B9F5A-6AC4-43A7-ABEC-E896B5E6A9A4 Q34556614-331A0283-1B84-4720-8389-D51850B663AC Q34641464-753C5D1F-3820-4368-B270-1B07BD6DBEB6 Q35241188-88AE1669-4513-4CEA-8952-00C22BDF44F4 Q35891553-787A0B58-E14F-4D54-9434-F1EFADA78FFE Q35962795-DF127CC1-E912-4E8D-86E8-D5D9776524B7 Q36182184-E219DC23-805B-46EB-98F4-674CFD235D93 Q36205262-FF3C3A64-BDAB-4D3B-9828-8833221FB972 Q36498512-D3C39358-0666-4639-9F0F-A60A1241475C Q36610624-8150CAC1-6FEA-41C7-81AA-F2E07360C1B5 Q36711673-895E15E1-B1BD-44DD-98F0-B24862BCE7F9 Q37099894-48D3A410-BDF4-4758-A704-51061B44BD2F Q37176629-153D45B7-7469-4B51-AE97-AF8EF2BD005F Q37260269-A32A53D5-3894-4BEE-8A44-0D3C8E22444E Q37279106-258D25B3-6D84-431D-B37C-0ADF6D282B9F Q37338551-603AEBF8-A57E-4B9B-A187-287A5BFE2EA8 Q37340172-08239DE1-FBF8-4FC2-9545-4DD2F30C74E8 Q37727924-496659CC-F979-4C7D-BA06-3EC8F41A5E46 Q38056493-4ACACAB6-695D-4792-B63B-D38685002480 Q38172403-ABB0946E-A072-4401-8090-62BBF424B0F6 Q38826590-C25885D4-1041-4D23-B5BD-A6FAADC740F6 Q38853235-0B221C9F-97F2-468C-A097-530C8CE8A727 Q39491072-AD43C339-A49E-42C8-8A00-98CBBF5CE578 Q40502560-8E881BF2-472F-4E93-B21E-43A07F0ADAA9 Q40987950-3F023558-BE76-4332-8C57-9B047E283440 Q41772314-1CC4A02C-6663-4736-9D15-E6ABDEACC0DC Q42131554-10D56E59-4B17-4196-8B28-6A7B582E8C5C Q42344691-F602863E-111A-4DCF-BA93-596B29D119CE Q46107442-1CBBFE3A-913B-4DAA-BEDF-A26C9FED29DC Q46243153-7DC4AC1B-0E6B-4F4C-8A65-15AB26D0F543 Q46341617-2E8CCCC5-E59B-47A9-A52F-C48892B5A57B Q46706302-26F90DFF-6423-4CBC-BF44-696E8A51A3A2 Q47107570-DCF687E5-B2CE-4BF9-A3AB-2C7182101E9B Q47176732-1BCB2DC7-A237-4A63-884D-E882D7D4707E Q47216784-77AF6F2D-2352-4975-8EDA-B27336533542

P2860

Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease

http://www.wikidata.org/entity/Q35985806

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease

@ast

Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease

@en

type

label

Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease

@ast

Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease

@en

prefLabel

Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease

@ast

Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease

@en

P1433

Q35985806-0E0BD3CD-04CC-4D20-B3AB-A02CC213AA58

P1476

Q35985806-FBDF8A43-CE7F-4BE6-9291-751EC9BD0DC0

P2093

Q35985806-653ACB5F-CD25-4544-AF12-5A83C63A9D5D

Q35985806-79319178-8568-4298-980D-1D8EE3524298

Q35985806-B72DE6E3-A6FD-44B3-861F-A7A53DA76E02

Q35985806-E308AD3F-766C-400E-9002-0532FB619C9C

Q35985806-E5638941-4B5C-4D98-8E9F-C7D2495563EA

Q35985806-E66C9BF4-2B98-44B3-9FE4-2AF9F1D9B698

Q35985806-ECEBE0FA-51DA-4A6C-B825-8CEF5FBCA0A9

Q35985806-F862F62B-9AFA-48BC-A831-893269714D6E

P2860

Q35985806-056A0A67-68D2-4397-9485-CD901B69E3FA

Q35985806-1032681A-1723-4C9A-815C-5F858F333EF3

Q35985806-12C5091F-427D-49B4-B905-E91D7E7A1586

Q35985806-12DD20E4-8E2B-4E4A-A9B8-32D64D5A4CBF

Q35985806-132DD55A-DFB9-4B9C-9787-5F96961DA004

Q35985806-15590A2F-4065-4E80-AB1D-5BA9B8237186

Q35985806-1BA86378-82E9-4748-A562-A3DA9D00A54E

Q35985806-1EDD7A53-6EE9-4D3D-B341-BEA6B74B00A5

Q35985806-2A940EEA-C04A-459A-AE11-CF32E8F13B9D

Q35985806-2D7071BB-9042-4DEC-8354-184C4A2FD370

P304

Q35985806-C523DBF1-A9CD-4F97-80CE-31340E84187B

P31

Q35985806-58FA51B0-22C9-4519-98F9-95C31E6BC552

P356

Q35985806-F3A1F8C0-FE3B-4E38-A193-B29102461943

P433

Q35985806-5B64E88E-85FF-42B9-B152-EAE1F3979708

P478

Q35985806-B5B0084E-6E45-40CC-9A20-D7366C150658

P50

Q35985806-6C3F81E1-17A9-4BC5-BE08-C1973FBB42D6

P577

Q35985806-0CF799D6-A320-42C7-B572-C98D4542365C

P698

Q35985806-52628071-C4AB-44E8-B68A-37DEBBF06083

P932

Q35985806-FE78342C-4A19-4B2F-A515-765AD5B7199C

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease

@en

P2093

Daniela V Barreto

http://www.w3.org/2001/XMLSchema#string

European Uremic Toxin Work Group (EUTox)

http://www.w3.org/2001/XMLSchema#string

Eva Schepers

http://www.w3.org/2001/XMLSchema#string

Fellype C Barreto

http://www.w3.org/2001/XMLSchema#string

Griet Glorieux

http://www.w3.org/2001/XMLSchema#string

Sophie Liabeuf

http://www.w3.org/2001/XMLSchema#string

Sunny Eloot

http://www.w3.org/2001/XMLSchema#string

Ziad Massy

http://www.w3.org/2001/XMLSchema#string

P2860

Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD

Atherosclerosis — An Inflammatory Disease

Inflammation in atherosclerosis

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification

Function and activation of NF-kappa B in the immune system

Increased reduction of dimethylarginines and lowered interdialytic blood pressure by the use of biocompatible membranes.

Symmetric dimethylarginine (SDMA) as endogenous marker of renal function--a meta-analysis.

Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?

Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine.

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.

P304

2374-2383

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.01720211

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Raymond Vanholder

P577

2011-08-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21817129

http://www.w3.org/2001/XMLSchema#string

P932

3359555

http://www.w3.org/2001/XMLSchema#string